Analyst
Jefferies
Equibles does not estimate personal net worth.
Benjamin Jackson is recorded as Analyst at Jefferies. Benjamin Jackson has spoken on 8 earnings calls across 5 companies, most recently for Galderma Group AG on October 22, 2026. Those appearances were for Genmab A/S (GMAB), Galderma Group AG (GALDY), IPSEN, Pharming Group N.V. (PHAR) and Zealand Pharma A/S (ZLDPF). The companies whose calls Benjamin Jackson spoke on are classified in the Healthcare sector.
“Fleming, I just wanted to ask on the level of confidence heading into that Relford S re-submission post this meeting with the FCA.”
“The first one on Rina-S, look, we've seen a couple of other companies make moves into drugs that look to overcome top-01 resistance.”
“The first, just a quick clarification when you're talking about 2027 growth. Can I just clarify whether Do you mean on like on an absolute basis when all is said and done post the transactions and the incremental spending?”
“I guess just another one, thinking about sequencing of drugs through the lines of therapies in DLBCL. We've heard from some docs that perhaps polyby is a very strong salvage option.”
“Please go ahead. brilliant thank you for the question guys i've got two if i may the first just on on refinance could you talk a little bit more about why you think you'll see further pressure in the second quarter on that sales line um and then why you think that you or what gives you the confidence of returning to…”
Jefferies
Analyst
Transcript header (unverified)
GMAB
Biotechnology · Healthcare
GALDY
Drug Manufacturers - Specialty & Generic · Healthcare
IPSEN
Drug Manufacturers - Specialty & Generic · Healthcare
PHAR
Biotechnology · Healthcare
ZLDPF
Biotechnology · Healthcare
Ipsen H1 2026 Results Call
IPSEN
